CD274 and pancreatic neoplasm: In the present study, the results demonstrated that the tumoricidal activity of a single immunotherapy antibody is insufficient; however, the anti-TNFR2 and anti-PD-L1 antibody combination showed unexpected curative effects, completely eliminating the disease and allowing long-term survival in multiple pancreatic tumor models.